Bicara Therapeutics Inc.(BCAX) - 2025 Q2 - Quarterly Results

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients expected by Q1 2026 Strong financial position with approximately $437 million in cash and cash equivalents as of June 30, 2025 expected to fund operations into the f ...